Results 11 to 20 of about 114,484 (186)

Bevacizumab [PDF]

The Oncologist, 2010
AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to ...
Kazazi-Hyseni, F., Beijnen, J.H., Schellens, J.H.M.   +2 more
core   +9 more sources

Bevacizumab for the Treatment of Glioblastoma [PDF]

Clinical Medicine Insights: Oncology, 2013
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months.
Gil Gil, Miguel, Mesia Barroso, Carlos, Rey, Montserrat, Bruna, Jordi   +3 more
openaire   +6 more sources

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Biologics: Targets & Therapy, 2008
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States.
Mary F Mulcahy
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Volker Heinemann, Paulo M. Hoff, Heinemann, Volker, Hoff, Paulo M.   +3 more
core   +1 more source

Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema [PDF]

, 2010
Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated
Haritoglou, Christos, Ulbig, Michael W., Kook, Daniel, Wolf, Armin, Neubauer, Aljoscha Steffen, Kreutzer, Thomas C., Al Saeidi, Rashid   +6 more
core   +1 more source

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]

, 2021
Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina, Beirão, João Nuno Melo, Pessoa, Bernardete, Figueira, João, Melo Beirão, João Nuno, Figueira, João P, Coelho, João, Monteiro, Sílvia, Coelho, Constança, Beirão, João, Malheiro, Luísa, Carneiro, Inês, João Coelho, Luísa Malheiro, Angelina Meireles, Sílvia Monteiro, João Figueira, Bernardete Pessoa, Inês Carneiro, Constança Coelho, João Nuno Melo Beirão   +20 more
core   +1 more source

Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma [PDF]

, 2011
Purpose: To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). Methods: Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (> 21 mm Hg)
Haritoglou, Christos, Wolf, Armin, Ulbig, Michael, Christos Haritoglou, Jagow, Burkhard von, Burkhard von Jagow, Michael Ulbig, Armin Wolf   +7 more
core   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: the BRVO study, a randomized trial [PDF]

, 2020
PURPOSE: Comparing the efficacy of intravitreal injections of bevacizumab to ranibizumab in the treatment of macular edema (ME) resulting from retinal vein occlusion (RVO).DESIGN: Comparative, randomized, double-masked, multicenter, noninferiority ...
Zwinderman, Aeilko H., Schauwvlieghe, Ann-Sofie M E, Peto, Tunde; id_orcid, Dijkman, Greetje, Zwinderman, Aeilko H, Schlingemann, Reinier O., Vingerling, Johannes R, Los, Leonoor I., Vingerling, Johannes R., Vader, Maartje J C, van Leeuwen, Redmer, van Lith-Verhoeven, Janneke J C, Lith-Verhoeven, Janneke J.C. van, Hooymans, Johanna M.M., Vader, Maartje J.C., Schauwvlieghe, A. nn-Sofie M.E., Hoyng, Carel B, Leeuwenhoek, Redmer van, Hooymans, Johanna M M, Verbraak, Frank D, Jong-Hesse, Yvonne de, Dijkgraaf, Marcel G.W., Los, Leonoor I, Peto, Tunde, Schlingemann, Reinier O, Dijkgraaf, Marcel G W, de Jong-Hesse, Yvonne, Verbraak, F.D. (Frank), Schauwvlieghe, AME, Los, LI, Vader, M.J.C. (Maartje J.C.), Leeuwen, R. (Redmer) van, Los, L.I. (Leonoor I.), Schlingemann, RO, Leeuwen, R. Van, van Leeuwen, R, Dijkgraaf, M.G., Schlingemann, R.O. (Reinier), Dijkman, G., Zwinderman, AH, Hoyng, C.B. (Carel), Lith-Verhoeven, J.J. van, de Jong-Hesse Y, van Lith-Verhoeven, JJC, Vingerling, J.R., Verbraak, FD, Peto, T., de Jong-Hesse, Y. (Yvonne), Dijkman, G, Hooymans, JMM, Lith-Verhoeven, J.J.C. (Janneke) van, Schauwvlieghe, A.M., Schauwvlieghe, ASME, Zwinderman AH, Vader MJC, Zwinderman, A.H., de Jong-Hesse, Y., Hooymans, J.M., Peto, T. (Tünde), Hooymans, JM, Los LI, van Lith-Verhoeven JJC, Dijkgraaf, MG, Dijkgraaf, MGW, Verbraak FD, Hoyng, C.B., Jong-Hesse, Y. de, Hoyng, CB, Vingerling, Hans, Vingerling JR, Vingerling, J.R. (Hans), de Jong-Hesse, Y, Schlingemann, R.O., Dijkman G, van Leeuwen, R., Dijkgraaf MGW, Vader, MJC, Schauwvlieghe AME, Peto T, Dijkgraaf, M.G.W. (Marcel), Los, L.I., Hoyng CB, Verbraak, F.D., Zwinderman, A.H. (Ailko), van Leeuwen R, Schlingemann RO, Vader, M.J.C., Hooymans, J.M.M. (Johanna), Peto, T, Hooymans JMM, Schauwvlieghe, A.M.E. (Ann-Sofie)   +90 more
core   +5 more sources

Bevacizumab (Avastin) [PDF]

American Journal of Neuroradiology, 2009
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire   +2 more sources